Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer - Inria - Institut national de recherche en sciences et technologies du numérique Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2020

Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer

Résumé

First-line antiproliferatives for non-small cell lung cancer (NSCLC) have a relatively high failure rate due to high intrinsic resistance rates and acquired resistance rates to therapy. 57% patients are diagnosed in late-stage disease due to the tendency of early-stage NSCLC to be asymptomatic. For patients first diagnosed with metastatic disease the 5-year survival rate is approximately 5%. To help accelerate the
Fichier principal
Vignette du fichier
Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer.pdf (1.41 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04387881 , version 1 (11-01-2024)

Licence

Paternité

Identifiants

Citer

Benjamin Schneider, Sébastien Benzekry, Jonathan Mochel. Comprehensive Joint Modeling of First-Line Therapeutics in Non-Small Cell Lung Cancer. 2024. ⟨hal-04387881⟩
14 Consultations
8 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More